NEW YORK--(BUSINESS WIRE)--BioSymetrics Inc., a biomedical AI company, today announced the formation of its Strategic Advisory Board (SAB). The newly-formed SAB will work closely with BioSymetrics’ leadership team to further the company’s mission of advancing healthcare and R&D innovation via machine learning and integrated analytics. The SAB is comprised of world-class clinicians, academic researchers, data scientists and healthcare technologists who are recognized for their leadership in cardiovascular medicine, neurosurgery, genomics, healthcare, biopharmaceuticals, and precision medicine.
Led by Chairman of the Board Anthony Iacovone, and Chief Scientific Officer Gabriel Musso, the following accomplished and well-credentialed members will provide scientific expertise and business counsel to BioSymetrics: Paul Boutros, MBA, PhD; Robert DeVita, MS, PhD; Chinnappa Kodira, MS; Calum MacRae, MD, PhD; and Gene Salkind, MD.
“We are honored to collaborate with visionary scientists whose R&D achievements and product innovations have contributed to advances in healthcare and medicine,” said Dr. Musso. “Our esteemed advisory board members will be leveraged as a strategic resource in market initiatives, and will add significant input and impact to the design of more BioSymetrics Data Science tools and Machine Learning solutions.”
Strategic Advisory Board Members:
Calum MacRae, MD, PhD is the Vice Chair for Scientific Innovation at Brigham and Women’s Hospital (BWH), an Associate Professor of Medicine at Harvard Medical School, and co-chair of BWH’s Genomic Medicine Program. Dr. MacRae’s lab at BWH is focused on understanding the mechanisms of cardiovascular disease and their therapy using human studies and complementary high-throughput biology in the zebrafish. As a member of the Harvard Stem Cell Institute, Dr. MacRae’s interests include the role of functional inputs, such as mechanical or electrical forces, in refining cardiovascular development. He is also the leader of the "One Brave Idea" project to fight coronary heart disease, a $75 million initiative funded by the American Heart Association, Verily, and Astra Zeneca.
Chinnappa Kodira, MS is the Managing Partner for an advanced analytics consultancy that serves life sciences and healthcare organizations. Most recently he served as Head of Computational Modeling, and Bioinformatics Strategy Leader at GE Global Research where he led the efforts on developing integrated data analytic solutions using omics, pathology, imaging and clinical data for accurate patient stratification, disease scoring and network modeling for research applications in oncology, immunology and neurodegenerative diseases. Prior to GE, his work included building first-in-class R&D applications for the reference human genome mapping, target identification and biomarker discovery at Celera Genomics, Roche Diagnostics and the Broad Institute of MIT and Harvard. At the Broad, he served as the Director of genome annotation where he led development and application of genome analysis pipelines for multiple high-profile genome projects. He was a key member of the early jumpstart phase of the Human Microbiome Reference Consortium. Earlier in his career, he did experimental and computational research at the National Center for Genome Resources (Santa Fe, New Mexico) and Sealy Center for Molecular Science.
Paul Boutros, MBA, PhD is a Principal Investigator at the Ontario Institute for Cancer Research (OICR), and Associate Professor in the Departments of Pharmacology and Toxicology, and Medical Biophysics at the University of Toronto. Dr. Boutros also serves as the co-lead of the Canadian Prostate Cancer Genome Network (CPC-GENE) and has led somatic mutation calling challenges for the worldwide bioinformatics community. Dr. Boutros’ laboratory uses genome-scale datasets to identify patient specific cancer biomarkers, allowing application of personalized therapeutics for all cancer types, although specifically focused on prostate cancer. His research focuses on novel methods for integrating predictive analytics, outcomes, and molecular biology into new diagnostic applications and oncology R&D advances.
Robert DeVita, MS, PhD is a Professor at the Icahn School of Medicine at Mount Sinai, in the Department of Pharmacological Sciences. He also serves as Director of the Medicinal Chemistry Core of the Drug Discovery Institute (DDI) at Mt Sinai, and is on the SAB of Circumvent, as well as being a co-founder of Attenua, Inc, and advisor for Mitokinin, Inc. Dr. DeVita has over 25 years of experience in the biopharmaceutical industry, including at Merck Research Laboratories as director of medicinal chemistry. His work spans the drug discovery paradigm from target identification through clinical stage development, and the identification of multiple development candidates including two Phase II clinical compounds for CNS and CV targets. Dr. DeVita also has experience in the discovery and development of PET imaging agents and translational biomarkers for CNS targets. He has developed, in collaboration with cross-disciplinary teams, orally active, brain penetrant, peripheral and GI tract drug targeting strategies. His R&D background across a range of therapeutic areas includes Oncology, CNS, pain, inflammation, diabetes, cardiovascular, hypertension, obesity, urology, and endocrinology.
Gene Salkind, MD currently serves as Chairman of Neurosurgery at Holy Redeemer Hospital in Pennsylvania. Dr. Salkind has practiced neurosurgery in the Philadelphia area for over 30 years, and previously served as Chairman of Neurosurgery at the Albert Einstein Medical Center. He has been a Director of DermTech International since May 2007 and serves on several other boards, including the SAB for Cure Pharmaceuticals. Dr. Salkind has published multiple papers and held professorships at leading teaching hospitals including the University of Pennsylvania Medical School.
“BioSymetrics is enabling healthcare organizations to intelligently manage large-scale complex data. I believe our machine learning methods and automated pre-processing framework will be a foundational part of biomedical digital transformation and future AI applications. I look forward to the contributions from this esteemed group of industry leaders to help us continue to excel,” said BioSymetrics’ Board Chairman Anthony Iacovone.
The BioSymetrics technology offering is a SaaS-based biomedical Machine Learning (ML) platform, Augusta™, that enables customers to perform automated ML and data pre-processing. Augusta’s automated iteration framework addresses the step in ML that is the most time consuming and error-prone, that of cleaning and pre-processing unstructured data for analysis. Augusta performs member-level predictive analytics on many kinds of R&D, precision medicine, and healthcare data. The Augusta platform can work from raw data formats, applies robust feature selection methods, and conducts integrated analytics on siloed data and complex data types e.g. compound chemistry, genomics, metabolomics, precision medicine, lab testing data, ECG/EKG, medical imaging data, and more. As outlined in a recent white paper, Augusta provides over 150 data modules.
About
BioSymetrics
BioSymetrics Inc. is based in New York,
Boston, and Toronto. Serving hospitals and health systems and
biopharmaceutical, precision medicine, and technology companies,
BioSymetrics is empowering healthcare and R&D innovation with leading
data science and analytics expertise, focused on making end-to-end
machine learning accessible to scientists and life sciences
organizations. For more information, visit www.biosymetrics.com
and Twitter @biosymetrics.
